MISTIE INTRACEREBRAL HEMORRHAGE TRIAL

Does faster clot removal in ICH give better patient outcomes?

Our next MISTIE II Safety Forum has been scheduled!

Please save the date for our

MISTIE III Safety Forum

To be held via webinar

Monday, September 12th at 6pm EDT

 

Registration link: https://attendee.gotowebinar.com/register/6527427076399367425  

 

Principal Investigator and M3 Neurosurgeon attendance is required.

Agenda:

TBD

84 Hits

Our next MISTIE III Quarterly Refresher will be held August 11!

Please join us for our next M3 Quarterly Refresher held August 11, 10am - 2pm EDT.

 

Click on the link below to register and choose from the drop-down menu the session you want to attend.  Once registered, details of the webinar will be e-mailed to you.

 

https://attendee.gotowebinar.com/rt/8885372643073065986

 

Future sessions of the M3 Quarterly Refresher will be held:

November 10, 2016

February 9, 2017

May 11, 2017

 

106 Hits

ACTION REQUIRED: M3 Monthly Webinar Links are EXPIRED

With the upgrade of our GoToMeeting/GoToWebinar accounts, the MISTIE III Monthly Webinars have been recreated. 

 

Please take a minute to re-register yourself for this important webinar.

 

8am: https://attendee.gotowebinar.com/register/1383745654482714115

2pm: https://attendee.gotowebinar.com/register/7592602054626842115

 

Once registered details of the call will be e-mailed to you.

 

As of July's Monthly Webinar, old webinar links will NOT work.  

137 Hits

Welcome to the EDGE Newton-2 Study!

Edge Therapeutics Logo

The BIOS team at Johns Hopkins University is delighted to be a part of Edge Therapeutics' clinical trial Newton-2 (Protocol #EG-01-1962-03) evaluating a new treatment for certain patients with aneurysmal subarachnoid hemorrhage (aSAH). Our goal at BIOS will be to ensure that the blinded assessors at the clinical sites are well versed on the neurologic outcome assessments in this trial. Because the outcome on the GOSE rating scale is the primary endpoint in this study, it is imperative that the assessor has a thorough understanding of the survey methodology, including the ability to perform a thorough assessment of the extent of disability at baseline, prior to the aSAH. We are providing this online training course, assessment tools, and informational updates. Please see the menu for these materials.

Additionally, please feel free to contact us with any questions you may have. Meanwhile, we look forward to working with you!

 

655 Hits

CLEAR-III Day-180 Results Presented at International Stroke Conference

CLEAR-III was all the talk at this year's International Stroke Conference (ISC). We had a number of presentations and posters discussing the Day-180 results of this six-year international multicenter trial exploring the delivery of alteplase, a thrombolytic ("clot buster"), via the extraventricular drain in patients with intraventricular hemorrhage (IVH). Thank you to all the clinical site staff and patients that contributed to this trial. There is alway more research needed when dealing with such a serious condition, but the knowledge gained on this project has been invaluable and will shape the future direction of future research for years to come.

Interview with Dr. Daniel Hanley, Co-principal Investigator for CLEAR-III

Photos of the team attending ISC

ISC Media Release

Abstracts and Slides  Dr. Hanley's presentation was LB12. Dr. Issam Awad's presentation was LB13

 Additionally, there have been lots of new articles about the CLEAR III results:

Continue reading
1579 Hits

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368